U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Mixture
Created
by admin
on Fri Jun 25 21:22:08 UTC 2021
Edited
by admin
on Fri Jun 25 21:22:08 UTC 2021
Record UNII
6D53G0FD0Z
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
PLASMA PROTEIN FRACTION (HUMAN)
WHO-DD  
Common Name English
PLASMA PROTEIN FRACTION HUMAN
Common Name English
PLASMA PROTEIN FRACTION,HUMAN [VANDF]
Common Name English
PLASMA, PROTEIN FRACTION (HUMAN)
Common Name English
PLASMA PROTEIN FRACTION (HUMAN) [WHO-DD]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 640.93
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
CFR 21 CFR 640.92
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
CFR 21 CFR 640.91
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
CFR 21 CFR 640.90
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
CFR 21 CFR 640.94
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
Code System Code Type Description
FDA UNII
6D53G0FD0Z
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
PRIMARY
DRUG BANK
DB13968
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
PRIMARY
RXCUI
33835
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
PRIMARY RxNorm
EVMPD
SUB127871
Created by admin on Fri Jun 25 21:22:20 UTC 2021 , Edited by admin on Fri Jun 25 21:22:20 UTC 2021
PRIMARY
All of the following components must be present:
Related Record Type Details
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
GLE is approximately 97.5% bound to human plasma proteins independent of concentration from 0.1 to 30 ?M (800 to 25,200 ng/mL).
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding for valdecoxib is about 98% over the concentration range (21-2384 ng/mL).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of relugolix is 68 to 71%, primarily to albumin and to a lesser extent to ?1-acid glycoprotein.
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
with no concentration dependence over the range of 100–500 ng/mL
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, human plasma protein binding was determined to be low (<18%) across a range of peramivir concentrations (10-1000 ng/mL) with no partitioning into red blood cells (Study DM99362).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Protein binding of tepotinib is 98% and is independent of drug concentration at clinically relevant exposures.
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
In vitro plasma protein binding of lonafarnib was greater than or equal to 99% over the concentration range between 0.5 to 40.0 ?g/mL.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Ivacaftor is approximately 99% bound to plasma proteins, primarily to albumin, and also to alpha 1-acid glycoprotein and human gamma-globulin.
BINDING
LIGAND->BINDER
Glasdegib is 91% bound to human plasma proteins in vitro
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The percentages ixabepilone bound to proteins at concentrations of 50, 500 and 5000 ng/mL were 76.6%, 72.0% and 67.1%, respectively. The protein binding of ixabepilone was not concentration dependent from 50 ng/mL to 5000 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
primarily to alpha-1-acid glycoprotein.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
BINDING
LIGAND->BINDER
Human plasma protein binding of pretomanid is approximately 86.4% and is independent of drug concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
in vivo
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
tezacaftor are approximately 99% bound to plasma proteins, primarily to albumin.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is independent on nelarabine concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The bound concentration increased slightly (,2%) as the concentration of 14C-rifapentine increased from 0.5 to 10 mg/ml. At concentrations above 10 mg/ml, protein binding did not appear to vary with increasing concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
For M16, protein binding was moderate and ranged from 82.6 to 85.7% 0.5 hr after avanafil administration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding was greater than 99% and is independent of plasma concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Reported not to bind to serum proteins
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDER->LIGAND
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ? 98% in healthy subjects and in subjects with renal or hepatic impairment.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Encorafenib is 86% bound to human plasma proteins and binding is not concentrationdependent
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Abametapir plasm protein binding ranged from 91.3 – 92.3% and was concentration independent within the tested concentration range of 50 – 800 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Miglustat does not bind to plasma proteins.
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Binding to human plasma proteins was low (approximately 22 %) and independent of the concentration of zoledronic acid.
BINDING
LIGAND->BINDER
Plasma protein binding is estimated to be 58% and was shown to be independent of plasma concentrations achieved following single and multiple oral doses of 200 mg or 300 mg (approximate range: 0.9-15 mg/ml).
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Protein binding of lemborexant is approximately 93.2% to 94.0% between 29 ng/mL and 71 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
The in vitro protein binding in human plasma is below 8% for tipiracil.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
~90% Gilteritinib bound to plasma proteins, mainly albumin
BINDING
LIGAND->BINDER
LIGAND->BINDER
SUB_CONCEPT->SUBSTANCE
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
independent of concentration
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of lorlatinib to human plasma proteins, including serum albumin and ?1-acid glycoprotein, was 66% at a concentration of 2.4 ?M.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
The human plasma protein binding of lasmiditan is approximately 55% to 60% and independent of concentration between 15 and 500 ng/mL.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of alvimopan was independent of concentration over ranges observed clinically and averaged 80% .
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding is 25% to 30% in the concentration range from 37 to 1850 ng/mL.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of selpercatinib is 97% in vitro and is independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro binding of gefitinib to human plasma proteins (serum albumin and ?1-acid glycoprotein) is 90% and is independent of drug concentrations.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of tivozanib is ? 99%, primarily to albumin in vitro and is independent of concentration.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
The protein binding of M1 is ~97% and is concentration independent.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The plasma protein binding of milnacipran is approximately 13% and is independent of the concentration (Study# M013).
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The protein binding is concentration dependent and decreases with increasing telaprevir concentrations at all concentrations of human serum albumin (HSA) and ?-1-acid glycoprotein (AAG). In addition, protein binding of telaprevir is affected by the concentration of HSA and AAG.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Cenobamate mainly binds with human albumin protein and not with ?1-acid glycoprotein.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
IN VITRO
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 ?g/mL).
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
Protein binding (primarily to serum albumin) of vericiguat is about 98%.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In human plasma, the binding of R093877 increased at higher pH values. In the pH-range 7.1 to 7.7, the percentage bound increased from 23.3% to 35.5%
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
PARENT -> BIOSIMILAR
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
independent of concentration
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
decreases as concentration increases
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, tazemetostat is 87.7 to 91.1% bound to human plasma proteins over the concentration range of 1 to 30 ?M.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro, protein binding of talazoparib is 74% and is independent of talazoparib concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
Binding to the latter protein is saturable, and the drug displays nonlinear kinetics with respect to plasma concentration and clearance.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The binding of Relebactam to human plasma proteins is approxi mately22% and is independent ofconcentration at a range of 5 to 50 ?M.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The plasma protein to whichSN-38 predominantly binds is albumin.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The mean plasma protein binding of vildagliptin in humans was low (9.3%) and also independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Total in vitro protein binding is approximately 60% to 70% and is primarily due to human serum albumin. Protein binding is not modified in elderly subjects and in patients with hepatic impairment.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Zanubrutinib is approximately 94.2% bound to human plasma proteins in vitro, independent of concentration.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
independent of capmatinib concentration
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
Binding of crizotinib to human plasma proteins in vitro is 91% and is independent of drug concentration.
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDER->LIGAND
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
Plasma protein binding of omadacycline is approximately 20% and is not concentration dependent.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro binding of gemifloxacin to plasma proteins in healthy subjects is approximately 60 to 70% and is concentration independent.
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
The in vitro protein binding in human plasma is greater than 96 % for trifluridine.
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
Protein binding of eravacycline to human plasma proteins increases with increasing plasma concentrations, with 79% to 90% (bound) at plasma concentrations ranging from 100 to 10,000 ng/mL.
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
BINDING
LIGAND->BINDER
BINDER->LIGAND
BINDING
LIGAND->BINDER
LIGAND->BINDER
LIGAND->BINDER
In vitro studies showed that docetaxel is about 94% protein bound, mainly to ?1-acid glycoprotein, albumin, and lipoproteins. In three cancer patients, the in vitro binding to plasma proteins was found to be approximately 97%.
BINDING